Learnings from the LOCOMOTIVE study:

Subgroup analyses:
Spot stenting with DCB in high risk patients

Gunnar Tepe, MD
Disclosure

Speaker name:
Gunnar Tepe

I have the following potential conflicts of interest to report:

Study support by:
Biotronic, BBraun, BD, BSC, Gore, Medtronic, Verian, Shockwave, Terumo
Stents in long lesions

Viastar
Lammer et al., CVIR 2015 38(1): 25-32

Result: all lesions

12-mo DUS

- Mean lesion length: 19 cm vs. 17.3 cm

Conclusion:
with increased lesion length: less patency
SFA stent performance related to lesion length

With standard stenting strategies, the patency rates decrease with stent length.


Note: Results from clinical trials are not directly comparable. This chart is for educational purposes only.
LOCOMOTIVE subgroup analysis: Spot Stenting in long vs. short lesions

fTLR @ 12 months: Spot Stenting in short and long lesions

- ≤ 10 cm: 89.4% (93/104)
- > 10 cm: 87.9% (175/199)

p = 0.701

Spot stenting is able to overcome the negative correlation between long lesions and reduced patency.
Spot Stenting in comparison to other stenting strategies

Note: Results from clinical trials are not directly comparable. This chart is for educational purposes only.
Drug effect on patency: DCB needed to optimize the stent result in standard therapy

Liistro et al. JACC 2013;6(12):1295-1302
LOCOMOTIVE subgroup analysis: POBA vs. DCB with Spot Stenting

Spot stenting works well with POBA as well as with DCB in long & complex fempop lesions
LOCOMOTIVE subgroup analysis:
Spot Stenting in long lesions with DCB

fTLR @ 12 months: Subgroup long lesions (> 10 cm)

84.6% (88/104) POBA long
91.6% (87/95) DCB long

p=0.132

Relevant drug effect comes with DCB & spot stenting in long & complex fempop lesions
LOCOMOTIVE subgroup analysis: Lesion Location

The best result is achieved with DCB + spot stenting in long SFA lesions.
Conclusions

Spot stenting overcomes the negative correlation between lesion length and reduced patency.

DCBs + spot stenting = ideal partners in long lesions.
Comparison of drug-eluting and bare metal stents for extracranial vertebral artery stenting

Prof. Piotr Pieniazek MD, PhD

Jagiellonian University Institute of Cardiology, John Paul II Hospital Krakow, Poland